iiinova — where your digital self keeps evolving

Chris Tape @christophertape.bsky.social · 26/09/2026

Super interesting study showing that dietary fats and ceramides can drive a YAP-mediated revival stem cell fate in CRC www.science.org/doi/10.1126/...

050

Chris Tape @christophertape.bsky.social · 24/09/2026

PhD opportunity in our lab at @ucl.ac.uk! 🧬 How do colorectal tumours spatially adapt to treatment? Study cancer cell plasticity using organoids, single-cell, & spatial biology. 4 years | Jan 2027 (flexible) | Stipend + UK home fees ucl.ac.uk/work-at-ucl/... Please share!

072

Chris Tape @christophertape.bsky.social · 19/06/2026

Together, we propose a causal, spatial mechanism for how inflammatory stromal niches grant non-genetic access to therapy-resistant, metastatic cell fates — and a mechanistic rationale for COX inhibition (aspirin/celecoxib) in both preventing and treating CRC. (7/7)

130

Chris Tape @christophertape.bsky.social · 19/06/2026

PTGS2+ CAFs map an epithelial plasticity gradient with increasing DACH1 in human CRC tumours. Specifically, epithelia <200 µm from PTGS2+ CAFs are revCSC and epithelia >200 µm are proCSC — linking stromal prostaglandin to poor-prognosis cell-fates in vivo. (6/7)

100

Chris Tape @christophertape.bsky.social · 19/06/2026

Full factorial analysis revealed that PGE2 is the dominant CAF regulator of CRC cell-fate. PGE2 rapidly and reversibly converts chemosensitive proliferative colonic stem cells (proCSCs) into chemorefractory, pro-metastatic revival colonic stem cells (revCSCs). (5/7)

110

Chris Tape @christophertape.bsky.social · 19/06/2026

We then built a single-cell arrayed CRISPR platform to interrogate native cell-cell communication. By perturbing the CAF secretome and measuring epithelial plasticity response, we identified CAF PTGS2 (COX2), HGF, GREM1, and IL1R1 as regulators of cell-fate. (4/7)

120

Chris Tape @christophertape.bsky.social · 19/06/2026

We developed a way to quantify CAF-induced plasticity in CRC epithelia and found that the transcriptional co-repressor DACH1 marks which cells are susceptible to CAFs: DACH1+ epithelia respond to stromal signals, DACH1– epithelia don't. (3/7)

100

Chris Tape @christophertape.bsky.social · 19/06/2026

Dozens of cancer-associated fibroblast (CAF) signals have been described in CRC, but the relative functional importance of each ligand on epithelial biology has been unclear. (2/7)

100

Chris Tape @christophertape.bsky.social · 31/03/2026

We are recruiting! We are searching for an exceptional postdoctoral fellow to lead the single-cell phenoscaping efforts of the REWIRE-CAN Cancer Grand Challenge @cancergrand.bsky.social For more information and to apply please visit: www.ucl.ac.uk/work-at-ucl/...

097

Chris Tape @christophertape.bsky.social · 04/03/2026

Today, one year on from that failed grant application and Bart’s ‘shall we explore?’ email, I am very proud to share that REWIRE-CAN has been supported by Cancer Grand Challenges. Never give up on an idea you believe in. (8/8)

3181

Chris Tape @christophertape.bsky.social · 04/03/2026

In December we pitched the project to the Cancer Grand Challenge committee in New York. At this point we’d spent so much time together that the team felt like a scientific family and I think that came across during the interview. (7/8)

130

Chris Tape @christophertape.bsky.social · 04/03/2026

For the next 9 months we worked together to create our Cancer Grand Challenge proposal. We went through many, many iterations — but learnt something new from every discussion and built something that none of us could ever have conceived alone. (6/8)

110

Chris Tape @christophertape.bsky.social · 04/03/2026

We brought together world-leaders in signalling activators (Bill Sellers, Roger Williams, Madelon Maurice, Steve Wedge) with experts in cancer cell models and signalling dynamics (Karuna Ganesh, Vivian Li, Smita Krishnaswamy) to form team REWIRE-CAN. (5/8)

110

Chris Tape @christophertape.bsky.social · 04/03/2026

Our idea was to use novel ‘activator’ drugs to ‘re-wire’ cancer cell signalling. This new class of therapies aim to turn the extreme signalling dependencies of cancer cells against them by hyper-activating signalling. We could also use activators to move cancer cells into vulnerable states. (3/8)

110

Chris Tape @christophertape.bsky.social · 04/03/2026

A few days later 7 new Cancer Grand Challenges @cancergrand.bsky.social were announced. I received an email from my UCL colleague Bart Vanhaesebroeck with an idea on how we might address the ‘Rewiring Cancer’ challenge. (2/8)

210

Chris Tape @christophertape.bsky.social · 04/03/2026

In early-2025 I was reeling from a ‘scored fundable’ grant application that was not funded. I really believed in this grant and knew the ideas were good but the review panel just weren’t into the project and there nothing more I could do. That’s science, but it hurts. (1/8)

4144

Chris Tape @christophertape.bsky.social · 10/12/2025

Annual lab curry ‘n’ karting. Incredibly privileged to work alongside these wonderful people

0120

Chris Tape @christophertape.bsky.social · 03/12/2025

It's been a HUGE privilege to interview for @cancergrand.bsky.social with the incredible REWIRE-CAN team

050

Chris Tape @christophertape.bsky.social · 31/10/2025

Paul Nurse describing the main job of a PI (From ‘The Thinking Game’, 2024)

218153

Chris Tape @christophertape.bsky.social · 25/10/2025

Important new paper from @batllelab.bsky.social showing how the KRAS-G12D inhibitor (RMC-9945) triggers rapid stem cell switching in CRC. This switch happens in just a few hours — similar to what we see with tumour cell responses to CAFs. aacrjournals.org/cancerdiscov...

0120

Chris Tape @christophertape.bsky.social · 14/10/2025

In summary, these results suggest that γδ T cell multimodal cytotoxicity can buffer γδ T cell signalling from patient-specific cancer cell immunomodulation, allowing γδ T cells from a range of donors to kill chemorefractory cancer cells. (12/13)

110

Chris Tape @christophertape.bsky.social · 14/10/2025

CRC PDOs comprise an admixture of chemosensitive proliferative colonic stem cells (proCSCs) and chemorefractory revival colonic stem cells (revCSCs). Crucially, stIL-15-γδ T cells can kill PDOs irrespective of stem cell admixture — including chemorefractory PDOs. (10/13)

110

Chris Tape @christophertape.bsky.social · 14/10/2025

To confirm that the anti-B7-H3 antibody was only inducing ADCC and not invoking the putative immune checkpoint properties of B7-H3, we also demonstrated that only a complete IgG — and not an Fc-null IgG — could trigger multimodal killing. (9/13)

120

Chris Tape @christophertape.bsky.social · 14/10/2025

Importantly, PDO immunomodulation of γδ T cells correlates with reduce AIC killing (i.e. the more PDOs change γδ T cell signalling, the worse γδ T cells kill). However, when γδ T cells also use AIC + ADCC, PTM signalling was restored and γδ T cells could kill all PDOs. (8/13)

110

Chris Tape @christophertape.bsky.social · 14/10/2025

We found that γδ T cells can kill both MSS and MSI CRC PDOs. However, when γδ T cells only use AIC, γδ T cell signalling converges on the target PDO, irrespective of T-cell donor. This suggests that γδ T cells are immunomodulated by PDOs and ITH is dominant over IDH. (7/13)

110

Chris Tape @christophertape.bsky.social · 14/10/2025

Next, we found that stIL15-engineered γδ T cells can rapidly kill MSI colorectal cancer (CRC) patient-derived organoids (PDOs) in 3D via AIC. Killing could be further increased by inducing ADCC via a novel anti-B7-H3 antibody — demonstrating multimodal cytotoxicity. (5/13)

120

Chris Tape @christophertape.bsky.social · 14/10/2025

First, we found that expressing stabilised IL-15Rα–IL-15 (stIL15) enables γδ T cells to survive in 3D cultures without serum or cytokine support. This is important because many T-cell killing assays are performed in 2D with serum, but tumours are 3D and nutrient-deprived. (4/13)

110

Chris Tape @christophertape.bsky.social · 14/10/2025

γδ T cells can kill cancer cells via antibody-independent cytotoxicity (AIC) and antibody-dependent cellular cytotoxicity (ADCC), but how this killing varies across T cell donors (inter-donor heterogeneity, IDH) and patients (inter-tumour heterogeneity, ITH) is unclear. (2/13)

110

Chris Tape @christophertape.bsky.social · 14/10/2025

Excited to share our new paper: ‘Phenoscaping Reveals Multimodal γδ T-cell Cytotoxicity as a Strategy to Overcome Cancer Cell–Mediated Immunomodulation’ led by Callum Nattress in collab. with Jonathan Fisher lab (1/13) aacrjournals.org/cancerres/ar...

182

Chris Tape @christophertape.bsky.social · 02/10/2025

Applications are now open for the @cruk-cityoflondon.bsky.social Black Leaders in Cancer PhD Programme. If you are interested in our project ‘Reprogramming Plasticity in Colorectal Cancer’ feel free to get in touch! www.colcc.ac.uk/2026-blic-ph...

056

Chris Tape @christophertape.bsky.social · 23/09/2025

Excited to be in Essen for @helloeacr.bsky.social Goodbye Flat Biology 🧫

091

Chris Tape @christophertape.bsky.social · 03/09/2025

A warm welcome to the newest member of the team: Lab-bubu

170

Chris Tape @christophertape.bsky.social · 07/08/2025

We are recruiting! Our lab is looking for a new mass cytometry technician to help study colorectal cancer organoid perturbation experiments at scale. Please feel free to contact me with any questions! Full job description and application details here: www.ucl.ac.uk/work-at-ucl/...

043

Chris Tape @christophertape.bsky.social · 26/06/2025

Incredibly impressed by the student/postdoc run @bacell3d.bsky.social conference. Great talks, a vibrant community, and so well organised 👏

0193

Chris Tape @christophertape.bsky.social · 23/06/2025

Congrats to Rhianna O’Sullivan for winning a poster prize at the UCL Cancer Institute conference! 👏

090

Chris Tape @christophertape.bsky.social · 23/05/2025

We are recruiting! We're searching for a postdoctoral research fellow to study patient-specific regulators of plasticity in primary and metastatic CRC. Please reach out if you have any questions! www.ucl.ac.uk/work-at-ucl/...

0710

Chris Tape @christophertape.bsky.social · 12/05/2025

Excited to arrive in Whistler for the @keystonesymposia.bsky.social on Organoids and Single Cells 🇨🇦 🐻

061

Chris Tape @christophertape.bsky.social · 01/05/2025

Congrats to Corinne Molyneux for winning a poster prize at the UCL Cancer Domain Symposium! 👏

040

Chris Tape @christophertape.bsky.social · 04/04/2025

Upgrade to our single-cell organoid dissociation factory 💥

0140

Chris Tape @christophertape.bsky.social · 31/03/2025

We are recruiting for a new Research Technician to join the @cruk-cityoflondon.bsky.social Organoid Platform! Full details at: www.ucl.ac.uk/work-at-ucl/...

0810

Chris Tape @christophertape.bsky.social · 03/03/2025

I think the CRC field ‘may’ have too many gene signatures

0131

Chris Tape @christophertape.bsky.social · 04/12/2024

Annual lab curry and new karting tradition. Extremely proud to work alongside these wonderful people.

0110

Chris Tape @christophertape.bsky.social · 03/12/2024

Excited to speak on the 'Single-cell Stage' at The Festival of Genomics & Biodata in London next month. Academic tickets are available free here: festivalofgenomics.com/london/en/pa...

0151

Chris Tape @christophertape.bsky.social · 27/11/2024

Fantastic update on advances in single cell proteomics from @jesperolsenlab.bsky.social

2162

Chris Tape @christophertape.bsky.social · 22/11/2024

The EMBL lift really embraces biological complexity

0170

Chris Tape @christophertape.bsky.social · 10/12/2023

Very excited to share two new papers from my lab describing stem cell plasticity in CRC. www.cell.com/cell/fulltex... www.cell.com/cell/fulltex...

2142